Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Humlová, Zuzana ^a,b   Klamová, Hana ^c   Janatková, Ivana ^b   Malíčková, Karin ^b   Králíková, Petra ^b   Šterzl, Ivan ^a   Roth, Zdeněk ^d   Hamíšková, Eva ^c   Vonka, Vladimír ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; C REACTIVE PROTEIN; DASATINIB; HUMAN IMMUNOGLOBULIN; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN; INTERLEUKIN 6; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; COMPLEMENT; IMMUNOLOGIC FACTOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; CANCER REGRESSION; CD3+ T LYMPHOCYTE; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE INCREASE; ERYTHEMA NODOSUM; FEMALE; HUMAN; LYMPHOCYTE; MALE; NEUTROPENIA; PRIORITY JOURNAL; BLOOD; IMMUNOLOGY; INNATE IMMUNITY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; HYDROXYUREA; IMMUNITY, INNATE; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTERLEUKIN-6; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; T-LYMPHOCYTES; THIAZOLES; TREATMENT OUTCOME;

EID: 79251541730     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/137320     Document Type: Article

References (46)

1. Suehiro M., Kishimoto S., Wakabayashi T., Ikeuchi A., Miyake H., Takenaka H., Okano A., Hirai H., Shimazaki C., Yasuno H., Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer British Journal of Dermatology 1998 139 4 748 749
2. Dacey M. J., Callen J. P., Hydroxyurea-induced dermatomyositis-like eruption Journal of the American Academy of Dermatology 2003 48 3 439 441
3. Talpaz M., McCredie K. B., Mavligit G. M., Gutterman J. U., Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia Blood 1983 62 3 689 692
4. Talpaz M., McCredie K., Kantarjian H., Trujillo J., Keating M., Gutterman J., Chronic myelogenous leukaemia: haematological remissions with alpha interferon British Journal of Haematology 1986 64 1 87 95
5. Bonifazi F., De Vivo A., Rosti G., Guilhot F., Guilhot J., Trabacchi E., Hehlmann R., Hochhaus A., Shepherd P. C.A., Steegmann J. L., Kluin-Nelemans H. C., Thaler J., Simonsson B., Louwagie A., Reiffers J., Mahon F. X., Montefusco E., Alimena G., Hasford J., Richards S., Saglio G., Testoni N., Martinelli G., Tura S., Baccarani M., Chronic myeloid leukemia and interferon- : a study of complete cytogenetic responders Blood 2001 98 10 3074 3081
6. Molldrem J. J., Lee P. P., Wang C., Felio K., Kantarjian H. M., Champlin R. E., Davis M. M., Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nature Medicine 2000 6 9 1018 1023
7. Burchert A., Wlfl S., Schmidt M., Brendel C., Denecke B., Cai D., Odyvanova L., Lahaye T., Mller M. C., Berg T., Gschaidmeier H., Wittig B., Hehlmann R., Hochhaus A., Neubauer A., Interferon-, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia Blood 2003 101 1 259 264
8. Wu C. J., Yang X.-F., McLaughlin S., Neuberg D., Canning C., Stein B., Alyea E. P., Soiffer R. J., Dranoff G., Ritz J., Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia Journal of Clinical Investigation 2000 106 5 705 714
9. Chakrabarti D., Hultgren B., Stewart T. A., IFN- induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2 Journal of Immunology 1996 157 2 522 528
10. Tosi D., Valenti R., Cova A., Sovena G., Huber V., Pilla L., Arienti F., Belardelli F., Parmiani G., Rivoltini L., Role of cross-talk between IFN- -induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens Journal of Immunology 2004 172 9 5363 5370
11. Sacchi S., Kantarjian H., O'Brien S., Cohen P. R., Pierce S., Talpaz M., Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia Journal of Clinical Oncology 1995 13 9 2401 2407
12. Tthov E., Kafkov A., tecov N., Friov M., Guman T., vorcov E., Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia Neoplasma 2002 49 2 91 94
13. Deininger M. W. N., Goldman J. M., Melo J. V., The molecular biology of chronic myeloid leukemia Blood 2000 96 10 3343 3356
14. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia New England Journal of Medicine 2002 346 9 645 652
15. Druker B. J., Talpaz M., Resta D. J., Peng B., Buchdunger E., Ford J. M., Lydon N. B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C. L., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia New England Journal of Medicine 2001 344 14 1031 1037
16. Nardi V., Azam M., Daley G. Q., Mechanisms and implications of imatinib resistance mutations in BCR-ABL Current Opinion in Hematology 2004 11 1 35 43
17. Gorre M. E., Mohammed M., Ellwood K., Hsu N., Paquette R., Nagesh Rao P., Sawyers C. L., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001 293 5531 876 880
18. Shah N. P., Tran C., Lee F. Y., Chen P., Norris D., Sawyers C. L., Overriding imatinib resistance with a novel ABL kinase inhibitor Science 2004 305 5682 399 401
19. Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., Griffin J. D., AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL British Journal of Cancer 2006 94 12 1765 1769
20. Kim P. S., Lee P. P., Levy D., Dynamics and potential impact of the immune response to chronic myelogenous leukemia PLoS Computational Biology 2008 4 6, article no. e1000095
21. Vonka V., Immunotherapy of chronic myeloid leukemia: present state and future prospects Immunotherapy 2010 2 2 227 241
22. Humlov Z., Klamov H., Janatkov I., Immunologic profiles of patients with chronic myeloid leukemia. I. State before the start of treatment Folia Biologica (Praha) 2006 52 3 47 58
23. Hamkov E., Ludvkov V., mahel M., Sapp M., Vonka V., Prevalence of antibodies to human Papillomaviruses in the general population of the Czech Republic International Journal of Cancer 1998 77 5 689 694
24. Steegmann J. L., Moreno G., Alez C., Osorio S., Granda A., De la Cmara R., Arranz E., Gmez Reino F., Rodriguez Salvans F., Fernndez-Raada J. M., Muoz C., Chronic myeloid leukemia patients resistant to or intolerant of interferon and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia Haematologica 2003 88 7 762 768
25. Nagasawa M., Mizutani S., Selective effect of imatinib on serum IgM in a patient with CML International Journal of Hematology 2004 80 4 381 382
26. Klsch A.-I., Soboletzki M., Schmitt W. H., Van Der Woude F. J., Hochhaus A., Yard B. A., Birck R., Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis? Clinical and Experimental Immunology 2008 151 3 391 398
27. Minh D. Q., Czink E., Mod A., Fust G., Hollan S. R., Serial complement measurements in patients with leukaemia Clinical and Laboratory Haematology 1983 5 1 23 34
28. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M., Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 Nature 1991 352 6333 345 347
29. Resnitzky D., Tiefenbrun N., Berissi H., Kimchi A., Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells Proceedings of the National Academy of Sciences of the United States of America 1992 89 1 402 406
30. Park S.-J., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S.-I., Kamimura D., Ueda N., Iwakura Y., Ishihara K., Murakami M., Hirano T., IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation Journal of Immunology 2004 173 6 3844 3854
31. Anand M., Chodda S. K., Parikh P. M., Nadkarni J. S., Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukaemia in different stages, and their role in prognosis Haematological Oncology 1998 16 4 143 154
32. Panteli K. E., Hatzimichael E. C., Bouranta P. K., Katsaraki A., Seferiadis K., Stebbing J., Bourantas K. L., Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases British Journal of Haematology 2005 130 5 709 715
33. Du Clos T. W., Mold C., C-reactive protein. An activator of innate immunity and a modulator of adaptive immunity Immunologic Research 2004 30 3 261 277
34. Szalai A. J., C-reactive protein (CRP) and autoimmune disease: facts and conjectures Clinical and Developmental Immunology 2004 11 3-4 221 226
35. Kleemann R., Gervois P. P., Verschuren L., Staels B., Princen H. M. G., Kooistra T., Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF B-C/EBP- complex formation Blood 2003 101 2 545 551
36. Reuben J. M., Lee B. N., Johnson H., Fritsche H., Kantarjian H. M., Talpaz M., Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukaemia in cytogenetic and haematologic remission with interferon-alpha, Clinical and Cancer Research 2000 6 5 1671 1677
37. Guarini A., Breccia M., Montefusco E., Petti M. C., Zepparoni A., Vitale A., Foa R., Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission British Journal of Haematology 2001 113 1 136 142
38. Pawelec G., Rehbein A., Schlotz E., Da Silva P., Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro Cancer Immunology Immunotherapy 1996 42 3 193 199
39. Kiani A., Habermann I., Schkel K., Neubauer A., Rogge L., Ehninger G., Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon- or imatinib Haematologica 2003 88 7 754 761
40. Seggewiss R., Lor K., Greiner E., Magnusson M. K., Price D. A., Douek D. C., Dunbar C. E., Wiestner A., Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner Blood 2005 105 6 2473 2479
41. Dietz A. B., Souan L., Knutson G. J., Bulur P. A., Litzow M. R., Vuk-Pavlovi S., Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo Blood 2004 104 4 1094 1099
42. Gu J. J., Zhang N., He Z. W., Koleske A. J., Pendergast A. M., Defective T cell development and function in the absence of Abelson kinases Journal of Immunology 2007 179 11 7334 7343
43. Sinai P., Berg R. E., Haynie J. M., Egorin M. J., Ilaria R. L. Jr. , Forman J., Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo Journal of Immunology 2007 178 4 2028 2037
44. Mumprecht S., Matter M., Pavelic V., Ochsenbein A. F., Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections Blood 2006 108 10 3406 3413
45. Chen J., Schmitt A., Giannopoulos K., Chen B., Rojewski M., Dhner H., Bunjes D., Schmitt M., Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner International Journal of Oncology 2007 31 5 1133 1139
46. Aswald J. M., Lipton J. H., Aswald S., Messner H. A., Increased IFN- synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia Cytokines, Cellular and Molecular Therapy 2002 7 4 143 149